In estrogen receptor-positive breast cancer (ER+ BC, of any stage) patients, we found that ~40% harbor defects in immune signaling at the time of diagnosis, including altered signaling responses to IL-6, IFNγ, TGFβ, IL-10, and IL-4 in various immune cells2,6. The gene discussed is IL6; the disease is breast cancer.